Antibodies targeting cancer stem cells: A new paradigm in immunotherapy?

mAbs

Volumn 1, Issue 1, 2009, Pages 12-25

  Deonarain, Mahendra P ^a   Kousparou, Christina A ^b   Epenetos, Agamemnon A ^a,b,c,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

^c Access Pharmaceuticals Inc   (United Kingdom)

^d Harley Street Oncology Clinic ^*  (United Kingdom)

Author keywords

Antibody; Cancer; Stem cell; Targeting; Therapy

Indexed keywords

ADECATUMUMAB; BIVATUZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; EDRECOLOMAB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYMECROMONE; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13M57; MONOCLONAL ANTIBODY 21M18; MONOCLONAL ANTIBODY 59M07; MONOCLONAL ANTIBODY ABC5; MONOCLONAL ANTIBODY AC133; MONOCLONAL ANTIBODY CD24; MONOCLONAL ANTIBODY CD44; MONOCLONAL ANTIBODY GKW A2; MONOCLONAL ANTIBODY H 460 16 2; MONOCLONAL ANTIBODY ING1; PACLITAXEL; RITUXIMAB; SOBLIDOTIN; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; LYMPHOMA; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953663505     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.1.7347     Document Type: Review

References (181)

1. Deonarain MP. Recombinant antibodies for cancer therapy. Expert Opin Biol Ther 2008; 8:1123-1141
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-357
3. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133:571-573
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70
5. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-799 (Pubitemid 39070849)
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-737 (Pubitemid 27298715)
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumourigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-3988 (Pubitemid 36418143)
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumourigenic prostate cancer stem cells. Cancer Res 2005; 65:10946-10951 (Pubitemid 41713363)
9. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110 (Pubitemid 46067310)
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
11. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-1037 (Pubitemid 46270758)
12. Dirks PB. Brain tumour stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 2008; 26:2916-2924
13. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760 (Pubitemid 44949604)
14. + breast cancerinitiating cells to radiation. J Natl Cancer Inst 2006; 98:1777-1785
15. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839-2845
16. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-447 (Pubitemid 38745529)
17. Brown JM, Giaccia AJ. The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-1416 (Pubitemid 28193601)
18. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002; 8:22-28 (Pubitemid 34101455)
19. Mimeault M, Hauke R, Mehta PP, Bhtra SK. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancer. J Cell Mol Med 2007; 11:981-1011. (Pubitemid 350037046)
20. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, wt al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173
21. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 2007; 1:555-567 (Pubitemid 350056407)
22. Dontu G. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. Distinct populations of cancer stem cells determine tumour growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-323 (Pubitemid 47355323)
23. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67. (Pubitemid 44942887)
24. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27:1749-1758
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 2007; 1:555-567 (Pubitemid 350056407)
26. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:25.
27. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11:1154-1159
28. + cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10:10.
29. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008; 26:2862-2870
30. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol 2002; 12:401-406
31. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008; 26:2871-2875
32. Kawano T, Yanoma S, Nakamura Y, Shiono O, Kokatu T, Kubota A, Furukawa M, Tsukuda M. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM- 1 and VCAM-1 as tumour markers in head and neck cancer. Am J Otolaryngol 2005; 26:308-313 (Pubitemid 41216016)
33. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumourigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761-765 (Pubitemid 44949605)
34. Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008; 26:2828-2838
35. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells Nature 2007; 444:111-115
36. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-10163 (Pubitemid 47175279)
37. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, et al. Colorectal cancer stem cells are enriched in xenogeneic tumours following chemotherapy. PLoS ONE 2008; 3:2428.
38. Huntly BJP and Gilliland DG. Leukemia stem cells and the evolution of Cancer Stem Cells. Nature Reviews Cancer 2005; 5:311-321 (Pubitemid 40488636)
39. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-2015
40. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. Isolation and characterization of tumourigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011-7021 (Pubitemid 39331011)
41. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA, Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005; 5:899-904. (Pubitemid 41746034)
42. Radtke F, Raj K. The role of Notch in tumourigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003; 3:756-767
43. Stylianou S, Clarke RB and Brennan K. Aberrant Activation of Notch Signaling in Human Breast Cancer. Cancer Research 2006; 66:1517-1525 (Pubitemid 43259933)
44. Chari NS, McDonnell TJ. The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol 2007; 14:344-352 (Pubitemid 47312290)
45. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006; 5:1026-1033
46. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127:469-80.
47. regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13:15-24.
48. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, et al. A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-414 (Pubitemid 36626987)
49. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423:302-305 (Pubitemid 40852701)
50. Sawa M, Yamamoto K, Yokozawa T, Kiyoi H, Hishida A, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005; 82:42-44 (Pubitemid 41512198)
51. Ehrlich P. Nobel Lectures. Physiology or medicine 1901-1921, 304-320 (Elsevier Publishing Co.,) Amsterdam 1967.
52. Kohler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
53. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/ human antibody. Nature 1984; 312:643-646 (Pubitemid 15218335)
54. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-327
55. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-1116 (Pubitemid 41486392)
56. Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 2002; 13:117-123 (Pubitemid 34310369)
57. Mufson RA. Tumour antigen targets and tumour immunotherapy. Front Biosci 2006; 11:337-343
58. Yang YM, Chang JW. Current status and issues in cancer stem cell study. Cancer Invest 2008; 26:741-755
59. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumours. Cancer 2007; 109:170-179 (Pubitemid 46106231)
60. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004; 35:211-231 (Pubitemid 40585308)
61. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:771-778 (Pubitemid 44086442)
62. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, Robert-Lezenes J, Chomienne C, Smadja-Joffe F. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004; 45:1501-1510 (Pubitemid 38885991)
63. Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C, Chomienne C, Smadja-Joffe F. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999; 5:669-676 (Pubitemid 29289431)
64. Kip1. Blood 2004; 103:1059-1068
65. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12:1167-1174 (Pubitemid 44527352)
66. Dick J. Patent US2007237761, 2007; University Health Network, France.
67. Young D. Patent WO2007098571, 2007; Arius Research Inc.
68. Rondon I. Patent, WO2004024750, 2004; Dyax Corp.
69. Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, et al. Tumour targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 2002; 20; 99:396-402. (Pubitemid 34495853)
70. Koppe M, Schaijk F, Roos J, Leeuwen P, Heider KH, Kuthan H, Bleichrodt R. Safety, pharmacokinetics, immunogenicity and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 2004; 19:720-729
71. Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, et al. Safety, biodistribution, pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003; 52:576-582 (Pubitemid 37056133)
72. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12:6064-6072 (Pubitemid 44703770)
73. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008; 44:823-829
74. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:771-778 (Pubitemid 44086442)
75. Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase and MMP-2. J Biol Chem 2008; 283:22513-22528
76. Guo Y, Ma J, Wang J, Che X, Narula J, Bigby M, Wu M, Sy MS. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994; 54:1561-1565 (Pubitemid 24106423)
77. Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllo si J, Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007; 43:2423-2433 (Pubitemid 47625976)
78. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008; 214:3-9.
79. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008; 86:1025-1032
80. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; (Epub ahead of print).
81. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ. Br J Cancer 2008; 99:100-109
82. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94:128-135 (Pubitemid 43088552)
83. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360:671-677 (Pubitemid 35232335)
84. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999; 77:699-712.
85. Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, et al. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 2003; 5:146-154
86. Goel S, Bauer RJ, Desai K, Bulgaru A, Iqbal T, Strachan BK, et al. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumours. Ann Oncol 2007; 18:1704-1707 (Pubitemid 47506259)
87. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006; 42:2530-2538 (Pubitemid 44442943)
88. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002; 100:101-110
89. Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 2008; 10:273-284 (Pubitemid 351799279)
90. Douville J, Beaulieu R, Balicki D. ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells. Stem Cells Dev 2008; In press.
91. + T-cell-defined tumour antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007; 67:10538-10545
92. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 2007; 1:555-567 (Pubitemid 350056407)
93. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26:1357-1360 (Pubitemid 46328461)
94. Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 2007; 21:2094-2102 (Pubitemid 47430452)
95. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-349
96. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35:255-262 (Pubitemid 40585311)
97. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006; 131:630-639 (Pubitemid 44142443)
98. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008; 68:2803-2812 (Pubitemid 351556279)
99. Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006; 119:314-325 (Pubitemid 43210700)
100. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613
101. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 2008; 26:2890-2894
102. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-3837 (Pubitemid 47332625)
103. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumour growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389-402. (Pubitemid 47506537)
104. Prokopchuk O, Liu Y, Henne-Bruns D and Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cells: evidence for autocrine and paracrine actions. Br J Cancer 2005; 92:921-928 (Pubitemid 40462640)
105. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26:2813-2820
106. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-280 (Pubitemid 43731112)
107. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51. (Pubitemid 47026733)
108. Korkaya H, Paulson A, Lovino F, et al. Cancer Cell (in press) Signalling regulates the mammary stem/progenitor cell population driving tumourigenesis and invasion 2008.
109. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27:5124-5131
110. Lewicki J. Patent WO2007145840, 2007; Oncomed Pharmaceuticals Inc.
111. Gurney A. Patent WO2008091641, 2008; Oncomed Pharmaceuticals Inc.
112. D'Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene 2008; 27:5148-5167
113. Gurney A. Patent WO2008042236, 2008; Oncomed Pharmaceuticals Inc.
114. Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007; 13:389-395
115. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444: 1083-1087 (Pubitemid 46018529)
116. Gurney A. Patent WO2007142711, 2007; Oncomed Pharmaceuticals Inc.
117. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6:7-14. (Pubitemid 38391944)
118. Nakamura M, Kubo M, Yanai K, Mikami Y, Ikebe M, Nagai S, et al. Anti-patched-1 antibodies suppress hedgehog signaling pathway and pancreatic cancer proliferation. Anticancer Res 2007; 27:3743-3747 (Pubitemid 47598439)
119. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95:1735-1740 (Pubitemid 28103463)
120. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1288-1296 (Pubitemid 30160621)
121. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, et al. Targeting, imaging and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007; 30:396-405. (Pubitemid 46684429)
122. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumour growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001; 98:2658-2663 (Pubitemid 32209538)
123. Murayama Y, Shinomura Y, Oritani K, Miyagawa J, Yoshida H, Nishida M, et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol 2008; 216:135-143 (Pubitemid 351813104)
124. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68:6043-6048
125. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14:109-119
126. Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol 2008; 26:2800-2805
127. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Proc Natl Acad Sci USA 2008; 105:2445-2450 Progenitor/stem cells give rise to liver cancer due to aberrant TGFbeta and IL-6 signaling.
128. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen- dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66:3087-3095
129. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30:607-613 (Pubitemid 47229695)
130. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008; 29:464-468
131. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumour cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008; 57:987-996
132. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007; 364:778-782 (Pubitemid 350103695)
133. Ossendorp F, Mengedé E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumours. J Exp Med 1998; 187:693-702. (Pubitemid 28115185)
134. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, et al. Antibodies selected from combinatorial libraries block a tumour antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006; 103:1041-1046 (Pubitemid 43212218)
135. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005; 21:605-631 (Pubitemid 41740648)
136. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007; 1:607-611 (Pubitemid 350215340)
137. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454
138. Riquelme PA, Drapeau E, Doetsch F. Brain micro-ecologies: neural stem cell niches in the adult mammalian brain. Philos Trans R Soc Lond B Biol Sci 2008; 363:123-137 (Pubitemid 350174578)
139. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumour cell cytotoxic effects reduce the tumour stem-like cell fraction in glioma xenograft tumours. Cancer Res 2007; 67:3560-3564 (Pubitemid 46762138)
140. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8:309-316
141. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400. (Pubitemid 38618122)
142. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, et al. Stem celllike glioma cells promote tumour angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66:7843-7848 (Pubitemid 44299144)
143. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumour stem cells. Cancer Cell 2007; 11:69-82. (Pubitemid 46054518)
144. Ceriani RL, Blank EW, Couto JR, Peterson JA. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Cancer Res 1995; 55:5852-5856
145. Neutzner M, Lopez T, Feng X, Bergmann-Leitner ES, Leitner WW, Udey MC. MFG-E8/ lactadherin promotes tumour growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis. Cancer Res 2007; 67:6777-6785
146. + progenitors to peripheral blood. J Exp Med 1997; 185:111-120
147. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007; 137:288-296 (Pubitemid 46650259)
148. Corcione A, Arduino N, Ferretti E, Pistorio A, Spinelli M, Ottonello L, et al. Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. Leuk Res 2006; 30:365-372 (Pubitemid 43254956)
149. Dittmar T, Heyder C, Gloria-Maercker E, Hatzmann W, Zänker KS. Adhesion molecules and chemokines: the navigation system for circulating tumour (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 2008; 25:11-32. (Pubitemid 351191223)
150. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56 (Pubitemid 32225831)
151. Honn KV, Tang DG. Adhesion molecules and tumour cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992; 11:353-375
152. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109:2708-2717 (Pubitemid 46482062)
153. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20:318-329
154. Ottaiano A, di Palma A, Napolitano M, Pisano C, Pignata S, Tatangelo F, et al. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother 2005; 54:781-791 (Pubitemid 40977146)
155. Huveneers S, Truong H, Danen HJ. Integrins: signaling, disease and therapy. Int J Radiat Biol 2007; 83:743-751
156. Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev 2007; 26:567-578 (Pubitemid 350115108)
157. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6:3056-3061 (Pubitemid 30637728)
158. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover and tumour cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003; 20:413-420
159. Cordes N, Seidler J, Durzok R, Geinitz H, Brakebusch C. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006; 25:1378-1390 (Pubitemid 43336466)
160. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007; 67:659-664 (Pubitemid 46192205)
161. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition
162. Oosterling SJ, van der Bij GJ, Bögels M, ten Raa S, Post JA, Meijer GA, Beelen RH, van Egmond M. Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg 2008; 247:85-94.
163. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003; 22:6598-6608 (Pubitemid 37372340)
164. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells.Nature 2005; 435:959-963
165. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5:997-1014. (Pubitemid 44835127)
166. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 7:7.
167. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98:3212-3220
168. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105:4163-4169 (Pubitemid 40720758)
169. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441:475-482 (Pubitemid 44050144)
170. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006; 12:4421-4425 (Pubitemid 44197192)
171. Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, et al. Phase I study of cetuximab, erlotinib and bevacizumab in patients with advanced solid tumours. Cancer Chemother Pharmacol 2008; In press.
172. Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 112:1288-1295
173. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol 2007; 25:390-394 (Pubitemid 350147114)
174. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43:481-489 (Pubitemid 46178540)
175. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006; 50:248-264 (Pubitemid 46157607)
176. Bhatti M, Yahioglu G, Milgrom LR, Garcia-Maya M, Chester KA, Deonarain MP. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int J Cancer 2008; 122:1155-1163
177. Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 2004; 4:1777-1789 (Pubitemid 39518111)
178. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2:214-221
179. Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Deonarain MP. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 2008; 19:643-650
180. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67:254-261 (Pubitemid 46142782)
181. Hart LS, El-Deiry WS. Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol 2008; 26:2901-2910